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Memantine is a low-affinity, voltage-dependent, non-competitive N-methyl-D-aspartate
(NMDA) receptor antagonist. It is classified as a neuroprotective aminoadamantane. It
does not cure or reverse Alzheimer’s but it does effectively treat symptoms, slows the
progression of the disease and allows many patients to perform daily cognitive activities
with clear thoughts. Based on it’s success in patients with Alzheimer’s, memantine has
been tested in other neurological disorders with impaired learning and memory. In this
review, we will discuss the success and failures of memantine in Downs Syndrome and
Fragile X research and from those results, assess the potential benefit of memantine in
Rett Syndrome (RTT).
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INTRODUCTION
Memantine was first synthesized in 1968 as a derivative of aman-
tadine, an anti-influenza agent (Lipton, 2004). It took nearly
15 years for scientists to discover that memantine was not
dopaminergic or anti-cholinergic but in fact a non-competitive
N-methyl-D-aspartate (NMDA) receptor antagonist. Proper
NMDA function is required for synaptic plasticity. Compared
to other NMDA receptor channel blockers such as ketamine
and phencyclidine (PCP), memantine has a lower affinity for
the receptor (Zdanys and Tampi, 2008). Memantine inhibits the
Ca2+ influx by binding the NMDA receptor with higher affin-
ity compared to Mg2+ions. Its low receptor affinity allows for
the preservation of the physiological function of the receptor.
The receptor can be activated by high concentrations of glu-
tamate released after depolarization of the presynaptic neuron
(Hosenbocus and Chahal, 2013).
Memantine is one of the primary pharmacological thera-
pies for Alzheimer’s disease. From an anatomical point of view,
Alzheimer’s disease distinguishes itself from other neurological
diseases in that the pathology is associated with atrophy in areas
of the brain important for learning and memory which is a direct
result of the molecular hallmarks of the disease: including the
development of amyloid plaques, tau hyper-phosphorylation, and
neurofibrillary tangles. For the most part, these three events are
believed to cause cerebral atrophy by destroying synapse and
dendrites, thus leading to the destruction of the entire neu-
ron. Current pharmacological therapy including drugs such as
donepezil, galantamine, or rivastigmine, which are classified as
cholinesterase inhibitors, in addition to memantine, are believed
to slow down these degenerative processes in the brain by alter-
ing calcium uptake into the neuron, or increasing the synaptic
concentration of acetylcholine (Cummings et al., 2002; Rogawski
and Wenk, 2003).
Memantine acts as a neuroprotectant by decreasing glutamate
excitotoxicity and has been known to increase levels of brain-
derived neurotrophic factor (BDNF) thus influencing synaptic
plasticity in rats, β-amyloid-induced apoptotic death and neu-
roinflammation in the hippocampus (Picada et al., 2011). In
the Morris water maze, memantine improved acquisition per-
formance, spatial accuracy, and increased durability of synaptic
plasticity (Sahiner et al., 2011). Over the past decade, meman-
tine drug trial research has been conducted in several neurological
disorders with cognitive disabilities including Down Syndrome
(DS), Fragile X Syndrome (FXS), and Rett Syndrome (RTT).
This review will focus on their results and future potential for
treatment in patients with RTT.
DOWN SYNDROME AND MEMANTINE
DS is the most common chromosome abnormality in humans
caused by the trisomy of human chromosome 21. DS is most
known for its effect on neurodevelopment but it also has a
neurodegenerative component, which includes neuropathology
indistinguishable from Alzheimer’s disease (Costa et al., 2008).
Nearly 40% of patients with DS over the age of 60 years also have a
diagnosis of dementia (Hanney et al., 2012). For patients with DS,
Alzheimer’s is the most common form of dementia (Mohan et al.,
2009). The gene Down Syndrome Critical Region 1 (DSCR1), a
chromosome 21 gene, has been thought to cause Alzheimer’s-
like pathology. The Ts65Dn mouse model of DS happens to have
three copies of the mouse ortholog DSCR1 (Costa et al., 2008).
The main pathological features of DS and the increased risk
of dementia are caused by the trisomy of chromosome 21 and
Alzheimer specific risk alleles, potentially involving the DSCR1
gene. This genotype gives way to an increase in amyloid β and
hyper-phosphorylation of tau tangles (Hanney et al., 2012). It is
important to note that people with DS overproduce amyloid β
because of gene dysregulation many of which are not linked to
Alzheimer’s.
EFFICACY OF MEMANTINE ON Ts65Dn MICE
Calcineurin (CaN) is a phosphatase that interacts with DSCR1
and its phosphatase activity is inhibited by loss of DSCR1 in DS,
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which alters the NMDA receptor kinetics. Memantine has pro-
duced changes on NMDA receptor kinetics that mimics CaN,
strongly suggesting a possible rescue of altered NMDA kinetics
in DS. In another study, memantine partially restored the physi-
ological function of the NMDA receptor and improved learning
and memory in mice (Costa et al., 2008). Three significant find-
ings emerged from this study, the first being that acutememantine
injections selectively improved the behavioral performance of
4–6 months old Ts65Dn mice in a contextual fear condition-
ing paradigm. Secondly, a memantine injection prior to the fear
conditioning session was found to be necessary in order to pro-
duce memory enhancement in the 4–6 months old Ts65Dn mice.
Lastly, to determine if there was an age dependence on the affects
demonstrated, acute memantine injections selectively improved
the performance of 10–14 months old Ts65Dn mice. The conclu-
sion of this study demonstrates that acute memantine injections
have the ability to rescue performance deficits in the Ts65Dn
mouse model.
MEMANTINE EFFECTS IN PATIENTS WITH DOWN SYNDROME
Human drug trials in patients with DS were published in 2012
(Hanney et al., 2012). The study researched the effects of meman-
tine on both patients over the age of 40 with DS and patients of
any age with DS and dementia. This double blind, randomized
drug trial ran for 1 year in Norway and the United Kingdom.
Unfortunately the benefits found in the mouse model research
were not translated into people with DS. Cognitive decline per-
sisted throughout the entire study in both patient groups.
The study did not find memantine to be useful, however drug
trials should not stop here. The research of Hanney et al. thus far
has not looked specifically at moderate to severe cases in patients
with DS and dementia. The patient groups they worked with
were patients over the age of 40 with DS and patients of any age
with DS and either diagnosed or undiagnosed dementia. Future
researchers should use a clearly defined patient pool with simi-
lar age diversity and include both moderate and severe cases of
dementia in patients with DS. In the future, larger cohort groups
need to be considered and further testing of various aspects of
the drug such as a study on cholinesterase inhibitors will push
memantine trials further. Studies should also address if mental
decline can be prevented by early administration of memantine.
FRAGILE X SYNDROME AND MEMANTINE
FXS is the most common single gene inherited cause of intellec-
tual disability among boys. FXS has a cysteine-guanine-guanine
(CGG) trinucleotide repeat in the fragile X mental retardation 1
gene (FMR1) located near the long arm of the X chromosome
(Erickson et al., 2009). Memantine is an appealing drug candi-
date for FXS treatment because FXS pathophysiology involves
glutamate receptor dysfunction. Since memantine is a noncom-
petitive antagonist at glutamate receptors, it has the potential to
aid symptoms associated with FXS.
FRAGILE X SYNDROME MEMANTINE TREATMENT IN MICE
Studies by Wei et al. on the FMR1 knockout mouse model, the
current model for FXS and investigated memantine’s effect on
cerebellar granule cells (CGCs) function. Cell adhesion assay and
cell migration assay as well as immunofluorescence were used in
this study to assess memantine’s effects on cells in culture. The
results revealed that memantine promoted CGCs adhesion, had
little effect on CGCs migration, restored dendritic spines to nor-
mal levels, stimulated synapse formation and restored excitatory
synapses to a normal range (Wei et al., 2012). One of the most
interesting results is that memantine was able to restore themush-
room spine density levels in the knockout mice to normal. This
property of memantine is similar to BDNF, which also aids in
the restoration of spines back to normal (Luine and Frankfurt,
2012). The results of memantine on the CGCs are promising
and they serve to further support the continuation of meman-
tine drug trials in humans. Further questions to be addressed
regarding memantine are the stimulation of synapse formation
and excitatory synapse as well as excitatory synaptic transmission.
MEMANTINE EFFECTS IN PATIENTS WITH FRAGILE X
An open-label memantine drug trial was conducted among six
patients with FXS (Erickson et al., 2009). Memantine was admin-
istered once a day starting at 5mg and increased every 2 weeks by
an additional 5mg until the presence of a clinical response or side
effects appeared, 20mg was the maximum dose. Routine check-
ups, CGI severity tests, and baseline and post-treatment Aberrant
Behavior Checklists (ABC) were used to analyze memantine’s
effects on patients. The average for all six participants across
the five categories of the ABC test, irritability, social withdrawal,
stereotypy, hyperactivity, and inappropriate speech decreased
from baseline scores to post-trial scores (Erickson et al., 2009).
Close examination of the patient specific data demonstrates
benefits of memantine use in four out of the six patients. In
patients 1 and 2, memantine significantly reduced irritability but
in patients 5 and 6 irritability increased (Erickson et al., 2009).
Patients 1, 2, 4 and 6 remained on other medications during
this study, which may have affected memantine’s effectiveness.
Clinical data in psychiatric non-Alzheimer disease conditions
often fail to support memantine as a monotherapy, this may be
why patient five results included increased irritability (Sani et al.,
2012) Memantine showed potential as a treatment for FXS how-
ever, the patient pool was too small therefore there is not enough
evidence to know which future patients would respond best to
this treatment.
RETT SYNDROME AND MEMANTINE
RTT was first described in 1954 by Dr. Andreas Rett. It was not
until 1999 that a team at Baylor found MECP2 on the X chro-
mosome, when mutated, to cause RTT (Zoghbi et al., 1999).
The X-linked geneMECP2 encodes for methyl-CpG-binding pro-
tein 2 (MeCP2), which is expressed throughout the body (Weng
et al., 2011). More and more studies are describing that MeCP2
regulates neuronal plasticity and that synaptopathy is a major
component of the Rett phenotype (Weng et al., 2011).
The use of memantine in RTT deserves a thorough examina-
tion, due in part to findings that have shown that glutamate levels
tend to be increased in RTT (Pan et al., 1999). Since above nor-
mal levels of glutamate can become toxic to the form and function
of neurons, reducing its downstream effects could be promising
therapeutically. Studies using male mice where the expression of
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Mecp2 was prevented, demonstrated that in vitro application of
memantine restored short-term plasticity as assayed by recov-
ery of post-tetanic potentiation and paired-pulse facilitation in
the hippocampus, the brain region critical for short-term plas-
ticity (Weng et al., 2011). Further advancement of this drug
or similar NMDA receptor antagonists in other preclinical tri-
als, more specifically in behavioral and motor assays, would
be of great interest to propel this drug class. Disease related
long term potentiation (LTP) deficits may be due to increased
tonic basal activation of post-synaptic NMDA receptors and
are amenable to reversal by the weak NMDA receptor-blocking
drug, memantine (Weng et al., 2011). Hippocampal slice cul-
tures from wild-type mice and Mecp2-stop mice were incubated
in a memantine solution. The wild-type slice cultures were not
affected by memantine but the Mecp2-stop slice cultures were
able to rescue LTP and post-tetanic potentiation. Memantine
was capable of partially reversing the synaptic deficits caused by
the loss of MeCP2. This data is supported by previous research
which demonstrated LTP saturation effects have been overcome
by memantine (Frankiewicz and Parsons, 1999).
Memantine has the potential to significantly impact future
RTT treatments. While studies have not investigated memantine’s
abilities to reverse some of the symptoms of RTT or to delay dis-
ease progression, their findings in memantine’s ability to partially
restore plasticity thus far are significant.
CONCLUSION
The non-competitive NMDA receptor antagonist, memantine has
the potential to restore synaptic plasticity and aid in the treatment
of diseases affecting learning and memory. Although meman-
tine improves conditions in diseases it should be emphasized that
memantine only improves upon symptoms thus far and that it
does not presently reverse or cure any diseases. Until the cures
for DS, RTT, and FXS are found, memantine research can lead
to a better understanding of these diseases, their pharmacological
interactions with other drugs, and aid in treating the symptoms
that affect both learning and memory.
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